BBIO Stock: Price, Earnings History and SEC Filings
BridgeBio Pharma, Inc. (BBIO) last traded at $74.95, up 5.97% on the latest session and up 13.9% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.42 against an analyst estimate of $-0.60, a beat of 30.0%.
$74.95 +5.97%
1 month+13.91%
52-week high$93.42
52-week low$60.22
Volume5.77M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BBIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-0.42 | $-0.60 | +30.00% |
| Jun 2026 | Aug 10, 2026 | $-0.78 | $-0.64 | -21.88% |
| Mar 2026 | May 7, 2026 | $-0.84 | $-0.70 | -20.00% |
| Dec 2025 | Feb 24, 2026 | $-1.00 | $-0.75 | -33.33% |
BBIO beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for BBIO
SEC filing data is not available right now. You can search for BBIO on SEC EDGAR.
BBIO news
- What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?Nov 1, 2026 · finance.yahoo.com
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysOct 30, 2026 · finance.yahoo.com
- BridgeBio (BBIO) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- BridgeBio Pharma, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings CallOct 30, 2026 · marketbeat.com
- BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesOct 29, 2026 · finance.yahoo.com
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- BridgeBio Pharma: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) is a US-listed public company on Nasdaq.